National and Kapodistrian University of Athens
Ο ρόλος του γλουταμικού οξέος στην ανάπτυξη μηνιγγιωμάτων και αστροκυττωμάτων
Abstract
dc:descriptionGliomas or astrocytomas are the most common and malignant group of primary brain tumors. Multiform glioblastoma (malignant glioma IV) is the fastest proliferating type of astrocytoma, which is also associated with the occurrence of epileptic seizures, rapid infiltration of cerebral parenchyma and particularly poor prognosis.Meningiomas are the most common benign tumors of the brain, surgical removal of which has very good results, with a five-year survival of over 90%. The local relapse of these tumors is particularly high and ranges from 11 to 29%.Glutamic acid (Glu) is the most abundant amino acid in the mammalian brain, playing the role of the major stimulant neurotransmitter. Increased levels of Glu in CSF have been associated with the regulation of cell proliferation, differentiation and survival of many neuronal tumors, including high-grade gliomas. Clinical studies on Glu levels in blood or cerebrospinal fluid (CSF) are very limited.The Special Protective Membrane Antigen (PSMA), known as folic acid hydrolase 1 or glutamate carboxypeptidase II (GCPII) or NAALA-Dase, is an enzyme (type II transmembrane glycoprotein) that breaks the N-acetyl-deparatamylglutaminate released into the N-acetyl aspartate and free Glu. PSMA is expressed very strongly in the endothelium of neovascular solid tumors, including gliomas but not in normal vessels. Binding of PSMA from naked or conjugated antibody to cytotoxin can be a powerful tool for vascular treatment of GBM.KLF8 (Krüppel-like factor 8) is a member of the KLF transcription factor family, which is involved in the proliferation of cancer cells and the penetration of gliomas. This double transcription factor is expressed in the gliomas of all grades of malignancy and its selective inhibition may be a new therapeutic strategy for malignant gliomas.The subject of the present study is: a) determination of glutamic acid (Glu) by HPLC in cerebrospinal fluid (ENY) and blood of glioma or meningioma brain; b) immunohistochemical identification of the presence of the Prostate Specific Membrane Antigen (PSMA) in brain tumor endothelial cells; c) immunohistochemical identification of the presence of KLF-8 (Krüppel-like factor 8) in the cells of benign and malignant CNS tumors; and d) the correlation of immunohistochemical markers with Glu levels in cerebrospinal fluid and blood glioma or meningioma patients.The findings of our study show that Glu concentrations in both CSF and blood plasma of glioma patients are higher than those in the CSF and in plasma of meningioma patients. This means that the production of glutamic acid at high concentrations is a property of predominantly malignant intraparenchymal tumors that develop by filtering normal brain tissue, as opposed to benign exoparenchymal tumors such as meningiomas, which usually do not infiltrate the parenchyma, and therefore do not cause epileptic seizures. In addition, it seemed that the more malignant a glioma is, the greater the Glu production, and the greater the concentration in the CSF of the affected patients.The results of the immunohistochemical study have shown that PSMA is expressed in neovasculars, not only gliomas but also meningiomas. The fact that the expression of PSMA involves all of the tumor vessels makes this factor likely a new therapeutic target. Since PSMA levels differ among patients we can hypothesize that the patients that would eventually benefit from such therapies are those with high PSMA.PSMA immunoreactivity score (IRS) did not show any significant correlation with Glu levels either in CSF or in blood, maybe due to our small number of samples. However, we noticed that the relationship between Glu and PSMA-IRS obeys in an hormetic or biphasic model which can manifest in different forms, like bell-shaped, U-shaped or J-shaped curves.In addition, our immunohistochemical results demonstrated for the first time, that KLF8, an important transcription factor recently found to be involved in the proliferation and spreading of glioma cells, is expressed not only in most gliomas (72%) of all degrees of malignancy, but also in 45% of meningiomas. The grade of KLF8 expression in glioma tissues associated with Glu concentration in CSF in an exponential way. This means that it might be possible to follow the response of anti-KLF8 therapy by measuring of Glu concentration in CSF at regular intervals.In conclusion, further research in larger groups of patients is needed to demonstrate the frequency of PSMA and KLf-8 expression in gliomas and meningiomas and their relation with glutamate. Thus in clinical perspective PSMA antagonists could be preoperatively used to reduce interfering intraoperative hemorrhage from neovascularization of both gliomas and meningiomas, and that anti-KLF8 agents might have a post-operative chemotherapy role, not only in gliomas, but also in atypical or malignant meningiomas.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dimogerontas, George
- Δημογέροντας, Γεώργιος
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41421